Apollo Therapeutics

Our CEO, Richard Mason, and CFO, Jamie Heath, will be attending the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California during January 13-16, 2025, along with senior leaders from our BD, R&D and Commercial Strategy teams.   Richard will be hosting a company presentation at the JPM Healthcare Conference at 11:00 PST on January 13, 2025 at Mission Bay (32nd Floor), The Westin St. Francis San Francisco, to provide an overview of the company and the incredible programs we are developing here at Apollo Therapeutics.   Please do let us know directly if you would like to connect at the conference. We look forward to seeing you there!   #JPMHealthcare #SanFrancisco #Conference

Last night Apollo Therapeutics and the University of Oxford held a launch event at Divinity School Oxford to celebrate our drug discovery and development collaboration which was announced in July 2024.   The evening included speeches from Professor Chas Bountra, Pro Vice-Chancellor for Innovation, and Matt Fuchter, Professor of Chemistry at the University of Oxford, as well as Apollo’s Richard Mason, Richard Butt, and Nadine Clemo.   This partnership marks our sixth collaboration with a world leading university, further bolstering our scalable R&D platform, and supporting our aim to translate breakthroughs in biology and basic medical research into innovative new medicines.   #UKscience #Collaboration #UniversityofOxford

Last night Apollo Therapeutics and the University of Oxford held a launch event at Divinity School Oxford to celebrate our drug discovery and development collaboration which was announced in July 2024.   The evening included speeches from Professor Chas Bountra, Pro Vice-Chancellor for Innovation, and Matt Fuchter, Professor of Chemistry at the University of Oxford, as well as Apollo’s Richard Mason, Richard Butt, and Nadine Clemo.   This partnership marks our sixth collaboration with a world leading university, further bolstering our scalable R&D platform, and supporting our aim to translate breakthroughs in biology and basic medical research into innovative new medicines.   #UKscience #Collaboration #UniversityofOxford

Tomorrow Apollo’s CFO, Jamie Heath, will be taking part in Ropes & Gray LLP's fireside chat on ‘Driving Value Creation and Incentive Alignment in Biotech Transactions: Strategies for Success’ during the 2024 Jefferies London Healthcare Conference.    Join the discussion on Wednesday, November 20 at 14:30pm at the Waldorf Hilton.   #JefferiesHealthcare 

We’re 3 days away from the 2024 European Lifestars Awards where Apollo Therapeutics has been nominated for the Later Stage Venture Round / Series C+ Finance Raise of the Year.   Good luck to all the finalists!   #LifestarsAwards

We’re delighted to announce that Apollo Therapeutics has entered into an exclusive licensing agreement for a clinical-stage FGF21 / GLP-1 dual receptor agonist bispecific fusion protein from Sunshine Lake Pharma.   Under the terms of the agreement, Apollo has been granted global (ex-China) development, manufacturing, and commercialization rights for APL-18881 for all current and future therapeutic indications, with Sunshine Lake retaining rights to the asset in China.   This transaction further delivers on our strategy to develop a large and diversified portfolio of novel therapeutic programs in areas of high unmet medical need, all with major commercial potential in large markets. APL-18881 brings our number of programs in clinical development to five.    To learn more, visit our website here: https://lnkd.in/eZjYZ5ku   #biotech #drugdevelopment 

From the city of dreaming spires to a tower of cash raised from its efforts, the technology transfer arm of the University of Oxford University today lifts the hood on the engine driving the local economy. Oxford University Innovation (OUI), raised around £900 million, filed scores of new patents and created more than 15 new companies in the year to July 2024. The figures are revealed in its 2024 report Shaping the Future: Oxford’s Innovation Impact. According to OUI’s preliminary output metrics, between August 2023 and July 2024 it raised £19.5m in seed funding and £872m in investment for companies, created 15 new companies (including 10 spinouts, two social ventures and three startups), filed 93 new patents, and struck 1,239 licensing deals spanning multi-sectors from HealthTech to clean energy. The report was unveiled at an Oxford Innovation Society (OIS) event for academic founders and leaders, venture capital investors and industry and ecosystem partners. Listing some of the achievements of the last 12 months, OUI’s new CEO, Dr Mairi Gibbs, welcomed the “launch of many potentially world-class companies”, including MatchBio, an Oxford University spinout that launched in January 2024 with a £4.5m investment to pioneer advancements in immunotherapy to fight cancer. She added that “OUI has been instrumental in securing agreements that extend the reach of our research”, pointing to a new licensing agreement between Oxford University and Cambridge biopharma company Apollo Therapeutics to accelerate the commercialisation of Oxford’s biomedical research by developing new therapies at pace. Dr Gibbs also cited technology developed by Onfido. Co-founders Eamon Jubbawy, Ruhul Amin and Husayn Kassai – former students at Saïd Business School, University of Oxford – launched the company in 2012 through OUI’s Startup Incubator. Over the past year, Onfido has helped prevent $3.9 billion in fraud losses for its global client base. It was acquired in April by global security company Entrust, marking the highest-value return to date on an Oxford University, student-led startup supported by OUI’s Incubator. The past 12 months have also seen the first deliveries of Oxford’s R21/Matrix-M malaria vaccine in Africa, following a licensing deal OUI negotiated with the Serum Institute of India Pvt. Ltd. OUI’s executive chair Baroness Nicola Blackwood said: “Over the past year, Oxford University Innovation has continued to play a pivotal role in transforming groundbreaking research into tangible economic and societal benefits, strengthening our position as a global leader in innovation.” https://lnkd.in/ekcQ49Jd

We’re delighted to announce that Apollo Therapeutics has entered into an exclusive licensing agreement for a clinical-stage FGF21 / GLP-1 dual receptor agonist bispecific fusion protein from Sunshine Lake Pharma.   Under the terms of the agreement, Apollo has been granted global (ex-China) development, manufacturing, and commercialization rights for APL-18881 for all current and future therapeutic indications, with Sunshine Lake retaining rights to the asset in China.   This transaction further delivers on our strategy to develop a large and diversified portfolio of novel therapeutic programs in areas of high unmet medical need, all with major commercial potential in large markets. APL-18881 brings our number of programs in clinical development to five.    To learn more, visit our website here: https://lnkd.in/eZjYZ5ku   #biotech #drugdevelopment 

We’re delighted to announce that Apollo Therapeutics has entered into an exclusive licensing agreement for a clinical-stage FGF21 / GLP-1 dual receptor agonist bispecific fusion protein from Sunshine Lake Pharma.   Under the terms of the agreement, Apollo has been granted global (ex-China) development, manufacturing, and commercialization rights for APL-18881 for all current and future therapeutic indications, with Sunshine Lake retaining rights to the asset in China.   This transaction further delivers on our strategy to develop a large and diversified portfolio of novel therapeutic programs in areas of high unmet medical need, all with major commercial potential in large markets. APL-18881 brings our number of programs in clinical development to five.    To learn more, visit our website here: https://lnkd.in/eZjYZ5ku   #biotech #drugdevelopment 

Tomorrow Apollo’s Stephen Shaw, VP, Program Leader and Head of Immunology, will be speaking at Cancer Research UK (CRUK)’s ‘Charting the pathways to patient impact: licensing and industry partnerships in translating research’ panel.   At Apollo, we match our world-class industrial drug discovery and drug development capabilities with basic medical breakthroughs made at our top university partners to create important new medicines.   Steve will be sharing his experience and insights of the importance of partnerships and collaborations between researchers and those in industry to deliver impact.   #Collaboration #Biotech